Focus: Bioserenity is a French biotech company specializing in epilepsy diagnosis and neurological monitoring through wearable sensor technology and digital biomarkers. The company operates as a pre-revenue or early-stage biotech focused on diagnostic devices rather than traditional pharmaceutical therapeutics.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Growing — net +16 jobs in 30d
20 jobs added vs 4 removed. Steady team buildout.
Best suited for early-stage explorers comfortable with high uncertainty and interested in digital health diagnostics; unsuitable for those seeking financial stability or clear career progression in traditional drug development.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bioserenity
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bioserenity's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo